Jild 3 № 1 (2026): Yanvar - Mart
92-100
2026-03-30
Ochiq kirish

Ishemik kardiomiopatiyada koronar revaskulyarizatsiya toʻliqligining kvadroterapiya fonida hayot sifati tiklanishiga taʼsiri

Xurshid G.Fozilov
Abdulatif M.Abdukomilov
Baxtiyor R.Atamuratov
https://doi.org/10.70626/cardiouz-2026-3-00081

Qabul qilingan: 2026-07-06

Nashr etilgan: 2026-03-30

PDF
Crossmark Crossmark

Annotatsiya

 


Maqsad. Ishemik kardiomiopatiya (IKMP) bilan kasallangan bemorlarda 6 oylik davolanish mobaynida bemor hayot sifati (KCCQ-12) qay darajada tiklanishini, koronar revaskulyarizatsiya to’liqligiga bog’liqligi, hamda uni belgilovchi mustaqil omillarni aniqlash.


Materiallar va usullar. Prospektiv bir markazli tadqiqotga IKMP bilan kasallangan 168 bemor kiritildi. Yurak jamoasi (Heart Team) bemorlarni uch guruhga ajratdi: 1-guruh – to’liq teri orqali koronar aralashuv (TOKA) (n=58), 2-guruh – to’liqsiz TOKA (n=54), 3-guruh – faqat OMT (n=56); barcha bemorlar SGLT2 ingibitori qabul qildi. Uzluksiz natijalar boshlang’ich qiymat hamda qoldiq SYNTAX ballga tuzatilgan ANCOVA yordamida, javob bashoratchilari logistik regressiya bilan tahlil qilindi.


Natijalar. 6 oyda KCCQ-12 barcha guruhlarda ishonchli ravishda oshdi (1-guruh +14,3; 2-guruh +9,5; 3-guruh +9,5 ball; guruh ichida barcha p<0,05); ≥5 ballga klinik ahamiyatli yaxshilanishga bemorlarning 53,7–63,8%i erishdi. Guruhlararo tuzatilgan KCCQ farqlari ahamiyatsiz bo’ldi (1- va 3-guruh: +3,28 ball; 95% CI −12,8–19,3; p=0,69). To’liq revaskulyarizatsiya qo’shimcha CHQOF o’sishi bilan bog’landi (1- va 3-guruh: +5,01%; 95% CI 1,17–8,84; p=0,01). KCCQ o’zgarishi CHQOF o’zgarishi bilan zaif, ammo ishonchli korrelyatsiyada edi (Spearman r=0,158; p=0,040). ≥10 ballga javobning yagona mustaqil bashoratchisi – pastroq boshlang’ich KCCQ (har bir ball uchun OR 0,91; 95% CI 0,88–0,94; p<0,001); revaskulyarizatsiya to’liqligi mustaqil bog’lanmadi.


Xulosa. SGLT2 ingibitori asosidagi kvadroterapiya fonida IKMP bilan kasallangan bemorlarda hayot sifati revaskulyarizatsiya to’liqligidan qat’i nazar sezilarli va o’xshash darajada yaxshilandi, to’liq revaskulyarizatsiya esa qo’shimcha chap qorincha teskari remodellanishini ta’minladi. Eng katta hayot sifati foydasi dastlab eng ko’p simptomga ega bemorlarda kuzatilgan bo’lib, bu shaxsiylashtirilgan, bemorga yo’naltirilgan qaror qabul qilishni qo’llab-quvvatlaydi.


 

Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Yan T, Zhu S, Yin X, Xie C, Xue J, Zhu M, et al (2023) Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the Global Burden of Disease 2019 Study. J Am Heart Assoc 12(6):e027852. https://doi.org/10.1161/JAHA.122.027852

  2. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert NM, et al (2021) Universal definition and classification of heart failure. Eur J Heart Fail 23(3):352–380. https://doi.org/10.1002/ejhf. 2115

  3. Pokharel Y, Khariton Y, Tang Y, Nassif ME, Chan PS, Arnold SV, et al (2017) Association of serial Kansas City Cardiomyopathy Questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials. JAMA Cardiol 2(12):1315–1321. https://doi.org/10.1001/jamacardio.2017.3983

  4. Green CP, Porter CB, Bresnahan DR, Spertus JA (2000) Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 35(5):1245–1255. https://doi.org/10.1016/S0735-1097(00)00531-3

  5. Spertus JA, Jones PG (2015) Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qual Outcomes 8(5):469–476. https://doi.org/10.1 161/CIRCOUTCOMES.115.001958

  6. Spertus JA, Jones PG, Sandhu AT, Arnold SV (2020) Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol 76(20):2379–2390. https://doi.org/10.1016/j.jacc.2020.09.542

  7. Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, et al (2018) Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol 3(6):498–505. https://doi.org/10.1001/jamacardio.2018.0398

  8. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303

  9. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424. https://doi.org/10.1056/ NEJMoa2022190

  10. Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al (2020) Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation 141(2):90–99. https://doi.org/10.1161/CIRCULATIONAHA. 119.044138

  11. Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, et al (2019) Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 140(18):1463–1476. https://doi.org/10.1161/CIRCULATIONAHA.11 9.042929

  12. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al (2021) Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 42(13):1203–1212. https://doi.org/10.1093/eurheartj/ehaa1007

  13. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627–3639. https://doi.org/10.1093/eurheartj/ehad195

  14. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol 79(17):e263–e421. https://doi.org/10.1 016/j.jacc.2021.12.012

  15. Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Brouse S, Butler J, et al (2024) 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction. J Am Coll Cardiol 83(15):1444–1488. https://doi.org/10.1016/j.jacc.2023.12.024

  16. Perera D, Clayton T, O’Kane PD, Greenwood JP, Weerackody R, Ryan M, et al (2022) Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med 387(15):1351–1360. https://doi.org/10.1056/NEJMoa2206606

  17. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al (2019) Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med 381(15):1411–1421. https://doi.org/10.105 6/NEJMoa1907775

  18. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al (2016) Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374(16):1511–1520. https://doi.org/10.1056/NEJMoa1602001

  19. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, et al (2019) Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med 381(8):739–748. https://doi.org/10.1056/ NEJMoa1807365

  20. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the ASE and EACVI. J Am Soc Echocardiogr 28(1):1–39. https://doi.org/10.1016/j.echo.2014.10.003

  21. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, et al (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 77(3):243–255. https://doi.org/10.1016/j.jacc.2020.11.008

Mualliflar haqida

Xurshid G.Fozilov
khurshidfozilov1976@icloud.com
Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi
Abdulatif M.Abdukomilov
abdulatif.abdukomilov@gmail.com
Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi
Baxtiyor R.Atamuratov
baxtiyor-cardio@mail.ru
Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi

Intervension kardiolog- RIKIATM rentgen endovaskulyar jarrohlik bo'limi

Litsenziya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Qanday iqtibos keltirish kerak

Ishemik kardiomiopatiyada koronar revaskulyarizatsiya toʻliqligining kvadroterapiya fonida hayot sifati tiklanishiga taʼsiri (X. Fozilov, A. Abdukomilov, & B. Atamuratov, Trans.). (2026). O’ZBEKISTON KARDIOLOGIYASI, 3(1), 92-100. https://doi.org/10.70626/cardiouz-2026-3-00081
Crossref
Scopus
Google Scholar
Europe PMC

Ushbu muallif(lar)ning eng koʻp oʻqilgan maqolalari

1 2 > >> 

O'xshash maqolalar

Siz ham ushbu maqola uchun {$ advancedSearchLink} olishingiz mumkin.

ISSN 3060-4850 (Print)